IRIDEX (IRIX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 12, 2026, with voting on director elections, auditor ratification, and executive compensation advisory vote.
Proxy materials are available online, with options for electronic or mail voting; record date is April 17, 2026.
17,395,350 shares of common stock and 600,000 shares of Series B Preferred Stock are outstanding and entitled to vote.
Voting matters and shareholder proposals
Five directors are nominated for election to serve one-year terms.
Ratification of BPM LLP as independent auditor for fiscal year 2026 is proposed.
Advisory vote on executive compensation (Say-on-Pay) is included.
Stockholders may submit proposals for the 2027 annual meeting by December 25, 2026, or nominate directors per bylaw procedures.
Board of directors and corporate governance
Board consists of five members, with all but the CEO considered independent.
Board committees include Audit, Compensation, Nominating and Governance, and Strategy and Budget.
Board leadership is separated, with an independent chairperson.
Board and committees held regular meetings, with all directors attending at least 75% of meetings.
Board encourages, but does not require, director attendance at annual meetings.
Corporate governance guidelines and a code of business conduct and ethics are in place.
Insider trading policy prohibits hedging, pledging, and certain derivative transactions.
Latest events from IRIDEX
- Operational efficiency and clinical innovation drive growth and recurring revenue expansion.IRIX
Planet MicroCap Las Vegas 202618 Jun 2026 - Innovative laser solutions and operational efficiencies drive growth and profitability in eye care.IRIX
Investor presentation4 Jun 2026 - Profitability achieved in Q4 2025, with strong growth in retina and glaucoma laser markets.IRIX
Lytham Partners Spring 2026 Investor Conference29 May 2026 - Q1 revenue stable at $11.8M; glaucoma growth offsets Retina headwinds; 2026 guidance reaffirmed.IRIX
Q1 202619 May 2026 - Votes on directors, auditor ratification, and executive pay set for June 12, 2026.IRIX
Proxy filing25 Apr 2026 - Strong 2025 revenue growth, first positive adjusted EBITDA, and positive cash flow outlook.IRIX
Q4 202526 Mar 2026 - Q2 revenue was $12.6M, net loss narrowed, and liquidity improved with new funding.IRIX
Q2 20242 Feb 2026 - Q3 revenue fell 10% year-over-year, but cost cuts and new reimbursement policies target Q4 breakeven.IRIX
Q3 202414 Jan 2026 - Q4 revenue and margins improved, with strategic investment supporting a positive 2025 outlook.IRIX
Q4 202424 Dec 2025